Clinical Trial Detail

NCT ID NCT01861314
Title Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

acute myeloid leukemia

Therapies

Bortezomib + Decitabine + Sorafenib

Age Groups: adult

No variant requirements are available.